Dendritic Cells explained, Provenge, Dandrit

By Stengaard On 9. June 2012 · 1 Comment · In DanDrit

Dandrit ‘s technique is based on Dendritic Cells, garland science made this easy-to-understand youtube video on the development of Dendritic Cells

http://www.youtube.com/watch?v=ZuccruG_79M

this stops at where the T-cells enters :)…

but don’t despair I’ve found another from KhanAcademy.org on the cytotoxic T-cells http://www.youtube.com/watch?v=xaz5ftvZCyI&feature=related (these are the cells that attack cancer-cells)

So far the only FDA approved vaccine is Provenge by Dendreon

http://www.youtube.com/watch?v=MTSc-hXxL3I

So far no video has been made on Dandrit’s MelCancerVac – lets hope a cash-infusion will change that – untill tehn we will have to make do with this written explanation of the process http://dandrit.dk/technology/vaccine-platform

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

More Posts(122)

One Response to Dendritic Cells explained, Provenge, Dandrit

Steinhof-I-pressume says:

9. June 2012 at 12:59

Dendreon (DNDN) faces competition from other large companies such as Johnson/Johnson – here is an interesting contrarian article about the progress of J&J's Zytiga …. http://seekingalpha.com/article/642161-asco-data-…

The overall conclusion from this catfight is that cancer vaccine will be a focus area. I've no doubt that this will eventually mean that Dandrit will be swallowed by one of the major players.

Based on the fact that Dendreon seems to have most to gain by keeping cometitors out of the market taht they see as theirs (being first movers) I see clear advantages for Dendreon by aquiring Dandrit

Reply